ENDP - Endo International plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9700
+0.0100 (+0.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9600
Open4.0100
Bid3.9200 x 4000
Ask4.1800 x 28000
Day's Range3.8900 - 4.0850
52 Week Range3.8300 - 18.5000
Volume5,066,048
Avg. Volume3,710,826
Market Cap897.943M
Beta (3Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-2.4290
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.08
Trade prices are not sourced from all markets
  • Here’s What Hedge Funds Think About Endo International plc (ENDP)
    Insider Monkey11 hours ago

    Here’s What Hedge Funds Think About Endo International plc (ENDP)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • GlobeNewswire2 days ago

    Nevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products

    BRIDGEWATER, N.J. and RALEIGH, N.C., June 18, 2019 -- Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Endo International PLC.

    Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $9.50 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Is Endo (ENDP) Down 38.9% Since Last Earnings Report?
    Zacks12 days ago

    Why Is Endo (ENDP) Down 38.9% Since Last Earnings Report?

    Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • CNW Group14 days ago

    Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month

    Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal. Endo Pharmaceuticals and Dr. Spitz encourage men to conduct self-penile exams to look for a curvature and feel for a lump this June, which is Men's Health Month.

  • This May Hurt a Little (Or a Lot) as Opioids Haunt Pharma Bonds
    Bloomberg28 days ago

    This May Hurt a Little (Or a Lot) as Opioids Haunt Pharma Bonds

    The investors are taking advantage of sliding prices for notes issued by companies such as Endo International Plc, Mallinckrodt Plc and Teva Pharmaceutical Industries Ltd., which face allegations that they’ve fueled the opioid epidemic, and that they’ve engaged in price-fixing of generic drugs. Mallinckrodt is also in a legal battle with the U.S. over a plan to slash reimbursements on Acthar, the company’s star drug.

  • Larry Robbins' Top 6 Buys of the 1st Quarter
    GuruFocus.com29 days ago

    Larry Robbins' Top 6 Buys of the 1st Quarter

    Guru makes real-time trade in Endo this month

  • CNW Grouplast month

    Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019

    DUBLIN , May 17, 2019 /CNW/ -- Endo International plc (ENDP) today announced that clinical data from a Phase 3 investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite will be presented by Lawrence Bass , M.D., a board-certified plastic surgeon with a practice in New York City . Dr. Bass will present the Phase 3 data during the Premier Global Hot Topics session, which takes place today from 1:00pm – 6:00pm (Central Time) at the New Orleans Ernest N. Morial Convention Center. The Hot Topics session is considered to be a highlight of The Aesthetic Meeting 2019, the annual meeting of the American Society for Aesthetic Plastic Surgery (The Aesthetic Society).

  • Introducing Endo International (NASDAQ:ENDP), The Stock That Tanked 91%
    Simply Wall St.last month

    Introducing Endo International (NASDAQ:ENDP), The Stock That Tanked 91%

    Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...

  • Endo International’s 2019 Key Growth Drivers
    Market Realistlast month

    Endo International’s 2019 Key Growth Drivers

    Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Endo International (ENDP) reported revenue of $720.41 million, a YoY (year-over-year) rise of 2.84% and $28.10 million higher

  • PR Newswirelast month

    Endo to Participate at RBC Healthcare Conference

    DUBLIN , May 15, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ENDP earnings conference call or presentation 9-May-19 11:30am GMT

    Q1 2019 Endo International PLC Earnings Call

  • Why Endo International Shares Are Under Pressure Today
    Motley Foollast month

    Why Endo International Shares Are Under Pressure Today

    Traders knock down the stock in response to an analyst downgrade.

  • Endo (ENDP) Q1 Earnings & Revenues Beat Estimates
    Zackslast month

    Endo (ENDP) Q1 Earnings & Revenues Beat Estimates

    Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.

  • Endo International (ENDP) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Endo International (ENDP) Q1 2019 Earnings Call Transcript

    ENDP earnings call for the period ending March 31, 2019.

  • Endo International (ENDP) Beats Q1 Earnings and Revenue Estimates
    Zackslast month

    Endo International (ENDP) Beats Q1 Earnings and Revenue Estimates

    Endo (ENDP) delivered earnings and revenue surprises of 26.19% and 4.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Endo: 1Q Earnings Snapshot

    The Dublin-based company said it had a loss of 8 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 53 cents per share. The results exceeded ...

  • Reuterslast month

    Drugmaker Endo posts narrower first-quarter loss

    Drugmaker Endo International Plc reported a smaller quarterly loss on Thursday, as sales of its sterile injectables and branded drugs rose. Net loss narrowed to $18.6 million, or 8 cents per share, for ...

  • Reuterslast month

    Drugmaker Endo quarterly results beat on robust sales of Xiaflex

    (Reuters) - Drugmaker Endo International Plc reported a first-quarter profit that beat analysts' estimates on Thursday, helped by growing sales of its drug Xiaflex and higher revenue at its sterile injectables ...

  • PR Newswirelast month

    Endo Reports First-Quarter 2019 Financial Results

    DUBLIN , May 9, 2019 /PRNewswire/ -- First-quarter 2019 revenues increased 3 percent to $720 million compared to first-quarter 2018 revenues of $701 million First-quarter 2019 Sterile Injectables revenues ...

  • There's misinformation out there on generic drugs: Association of Accessible Medicines CEO
    CNBC Videoslast month

    There's misinformation out there on generic drugs: Association of Accessible Medicines CEO

    CNBC's "Power Lunch" team discusses generic drug makers' price fixing allegations with Chester "Chip" Davis, CEO of the Association of Accessible Medicines.